Alpha-1 Lung Disease: Symptoms, Causes, Diagnosis and Treatment
Looking for a printable version of this information? Download our free fact sheet.
Alpha-1 Antitrypsin Deficiency (Alpha-1) is a genetic condition that can affect both the lungs and liver. While not everyone with Alpha-1 develops lung disease, around half of people with severe Alpha-1 deficiency may experience lung-related complications during their lifetime.
Many people with Alpha-1 are initially diagnosed with asthma, chronic bronchitis or emphysema before the underlying cause is identified. Understanding how Alpha-1 affects the lungs can help individuals seek appropriate testing, treatment and support.
Download the Alpha-1 Lung Disease Fact Sheet (PDF).
What Is Alpha-1 Antitrypsin Deficiency?
Alpha-1 Antitrypsin Deficiency (AATD or Alpha-1) is an inherited genetic condition passed from parents to their children. It affects the body’s ability to produce enough Alpha-1 Antitrypsin (AAT), a protein that helps protect the lungs from damage.
When there is not enough AAT circulating in the body, the lungs become more vulnerable to inflammation and injury, increasing the risk of developing chronic lung disease.
How Does Alpha-1 Cause Lung Disease?
Alpha-1 Antitrypsin is produced primarily in the liver and released into the bloodstream. One of its most important roles is protecting the lungs from a naturally occurring enzyme called neutrophil elastase.
Neutrophil elastase is released by white blood cells to help fight infections and remove damaged tissue. Under normal circumstances, Alpha-1 Antitrypsin keeps this enzyme under control.
In people with Alpha-1 Deficiency, there may not be enough Alpha-1 Antitrypsin available to protect the lungs. As a result, neutrophil elastase can gradually damage healthy lung tissue, including the delicate air sacs responsible for oxygen exchange.
Over time, this damage can lead to conditions such as emphysema, chronic bronchitis and bronchiectasis.
Symptoms of Alpha-1 Lung Disease
Symptoms can vary from person to person and may develop gradually over many years.
Common symptoms include:
- Shortness of breath
- Persistent cough
- Excess phlegm or mucus production
- Wheezing
- Frequent chest infections
- Reduced exercise capacity
- Fatigue
- Asthma-like symptoms
- Chest discomfort
- Night sweats
- Coughing up blood
If you have ongoing respiratory symptoms, particularly if there is a family history of Alpha-1, speak with your healthcare professional about testing.
Lung Conditions Associated with Alpha-1
Emphysema
Emphysema is one of the most common lung conditions associated with Alpha-1. It occurs when the air sacs (alveoli) in the lungs become damaged and lose their elasticity.
This damage makes it harder to breathe out fully, trapping air in the lungs and reducing the body’s ability to absorb oxygen efficiently.
Smoking, exposure to dust, fumes and environmental pollutants can accelerate the progression of emphysema in people with Alpha-1.
Bronchiectasis
Bronchiectasis is a chronic condition where the airways become widened and damaged. This can lead to increased mucus production, recurrent chest infections and ongoing inflammation.
People with Alpha-1 may be at a higher risk of developing bronchiectasis due to the increased inflammatory activity occurring within the lungs.
Chronic Bronchitis
Chronic bronchitis involves long-term inflammation of the airways and is characterised by ongoing cough and mucus production.
Because Alpha-1 can increase inflammation within the lungs, some individuals may experience symptoms of chronic bronchitis alongside other respiratory conditions.
Lung Hyperinflation
Lung hyperinflation occurs when air becomes trapped inside the lungs. This can happen when damaged air sacs lose their ability to recoil properly during breathing.
As more air becomes trapped, the lungs can become overinflated, making breathing increasingly difficult and contributing to feelings of breathlessness.
How Is Alpha-1 Lung Disease Diagnosed?
Several tests may be used to assess lung health and identify complications associated with Alpha-1.
These may include:
- Lung function testing (spirometry)
- FEV1 testing
- DLCO testing
- Chest X-rays
- CT scans of the lungs
Your healthcare team will determine which tests are most appropriate based on your symptoms and medical history.
Treatment Options for Alpha-1 Lung Disease
Treatment depends on the severity of symptoms and the specific lung condition involved.
Potential treatment options include:
Augmentation Therapy
Augmentation therapy involves regular infusions of Alpha-1 Antitrypsin protein derived from human plasma.
The aim is to increase protective AAT levels in the bloodstream and help slow the progression of emphysema in eligible individuals.
Prompt Treatment of Infections
Chest infections can accelerate lung damage in people with Alpha-1. Early assessment and treatment of respiratory infections may help reduce complications.
Pulmonary Rehabilitation
Pulmonary rehabilitation programs combine exercise, education and support to help people improve their breathing, fitness and quality of life.
Lung Valves
In some cases, lung volume reduction procedures using specialised valves may help improve breathing by reducing the impact of severely damaged lung tissue.
Lung Transplantation
For individuals with advanced lung disease, lung transplantation may be considered as a treatment option.
How to Protect Your Lung Health
There are several steps people with Alpha-1 can take to support their respiratory health:
- Do not smoke
- Avoid exposure to dust, fumes and chemicals where possible
- Exercise regularly
- Attend pulmonary rehabilitation if recommended
- Seek treatment early for respiratory infections
- Follow your healthcare team’s advice regarding vaccinations and ongoing monitoring
Looking for a printable version of this information? Download our free fact sheet.
Frequently Asked Questions
Common questions about Alpha-1 lung disease, diagnosis and treatment in Australia.
What is Alpha-1 Antitrypsin Deficiency and how does it affect the lungs?
Alpha-1 Antitrypsin Deficiency (AATD or Alpha-1) is an inherited genetic condition that reduces the body’s ability to produce enough Alpha-1 Antitrypsin (AAT) — a protein made in the liver that protects the lungs from damage. Without sufficient AAT, an enzyme called neutrophil elastase can gradually destroy healthy lung tissue, increasing the risk of chronic lung diseases such as emphysema, bronchiectasis and chronic bronchitis.
What are the early signs of Alpha-1 lung disease?
Early symptoms of Alpha-1 lung disease include persistent shortness of breath, a chronic cough, excess mucus production, wheezing and reduced exercise tolerance. Many people with Alpha-1 are initially misdiagnosed with asthma or COPD before the underlying genetic cause is identified. If symptoms persist — particularly with a family history of lung or liver disease — testing for Alpha-1 is recommended.
How is Alpha-1 lung disease diagnosed?
Alpha-1 lung disease is typically diagnosed through a combination of genetic blood testing to confirm the deficiency and lung function tests to assess respiratory impact. These may include spirometry, FEV1 testing, DLCO testing, chest X-rays and CT scans of the lungs. A healthcare professional will determine the appropriate tests based on individual symptoms and medical history.
What treatments are available for Alpha-1 lung disease in Australia?
Treatment for Alpha-1 lung disease in Australia may include augmentation therapy (regular infusions of AAT protein derived from human plasma to help slow emphysema progression), pulmonary rehabilitation, early treatment of chest infections, lung volume reduction using valves, and in advanced cases, lung transplantation. Treatment is tailored to the individual based on the severity of their condition. Australians with Alpha-1 should speak with a respiratory specialist about their eligibility for available therapies.
Does smoking make Alpha-1 lung disease worse?
Yes. Smoking significantly accelerates lung damage in people with Alpha-1 and is one of the most important preventable risk factors for worsening the condition. Exposure to dust, chemical fumes and environmental pollutants can also speed up disease progression. People with Alpha-1 are strongly advised not to smoke and to minimise exposure to airborne irritants.
What is augmentation therapy for Alpha-1?
Augmentation therapy is a treatment for Alpha-1 that involves regular intravenous infusions of Alpha-1 Antitrypsin protein sourced from human plasma. The goal is to raise AAT levels in the bloodstream to help protect the lungs from ongoing damage and slow the progression of emphysema in people with severe Alpha-1 deficiency. It is currently the only disease-specific therapy available for Alpha-1 lung disease.
How common is Alpha-1 in Australia?
It is estimated that around 1 in 9 Australians carries a faulty Alpha-1 gene, and approximately 4,000 Australians have the most severe form of the condition (the ZZ genotype). Despite this, Alpha-1 remains significantly underdiagnosed. Lung symptoms most commonly appear in adults in their 40s and 50s, though the condition is present from birth.
Who should be tested for Alpha-1?
Testing for Alpha-1 is recommended for anyone with unexplained emphysema, COPD or bronchiectasis — especially those diagnosed at a younger age, non-smokers or light smokers with lung disease, people with a family history of Alpha-1 or unexplained liver disease, and individuals with asthma that does not respond well to treatment. A simple blood test can confirm an Alpha-1 diagnosis.
About the Author, Gaynor Heading
Gaynor Heading holds a PhD in Medicine and is President of Alpha-1 Organisation Australia. She is a former Associate Professor with the University of Sydney with publications in respiratory health and health professional education, and has held competitive research grants including an NH&MRC grant. She brings extensive experience in public health, consumer advocacy and community liaison.